Filing Flows › Mirum Pharmaceuticals (MIRM) › Q2 2025
Mirum Pharmaceuticals (MIRM) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 6, 2025
Mirum Pharmaceuticals (MIRM) reported revenue of $128M for the second quarter 2025 (Q2 2025), +64% from a year earlier and +15% from the quarter before. Operating margin was -3.9%, net loss $5.9M (4.6% of revenue).
Mirum Pharmaceuticals, Q2 2025: revenue $128M (+64% year over year), operating margin -3.9%, net loss $5.9M, operating cash flow $12.0M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $128M | +15% | +64% |
| Operating profit | −$5.0M | — | — |
| Net earnings | −$5.9M | — | — |
| Operating cash flow | $12.0M | — | — |
| Free cash flow | $11.9M | — | — |
What changed
Revenue was $127.8M in Q2 2025, up 64% year over year and up 15% from the previous quarter. Livmarli was the largest line at 69% of revenue. Livmarli added $40.9M year over year (up 87%), 82% of the total change.
Operating costs exceeded revenue by $5.0M, an operating margin of -3.9%. Total costs grew 30% against revenue growth of 64%. The fastest-growing cost line was Research & development (+41%). The quarter ended with a net loss of $5.9M, narrower than the previous quarter's $14.7M loss.
Operating cash flow was $12.0M. Non-cash charges added back $6.1M of depreciation and amortization and $18.5M of share-based compensation. Working capital and other items used $6.6M. Capital expenditures of $126K left free cash flow of $11.9M.
Questions
What was Mirum Pharmaceuticals' revenue in the second quarter 2025?
Mirum Pharmaceuticals (MIRM) reported revenue of $128M for the second quarter 2025 (Q2 2025), +64% from a year earlier and +15% from the quarter before.
Was Mirum Pharmaceuticals profitable in the second quarter 2025?
Operating loss was $5.0M (-3.9% of revenue) and net loss $5.9M.